{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "a-synuclein",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "a-synuclein E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "a-Synuclein is the major component of the filamentous Lewy bodies and Lewy neurites that define Parkinson’s disease and dementia with Lewy bodies at a neuropathological level.",
          "judgment": "Yes",
          "reasoning": "The paper clearly states the role of a-synuclein in the pathology of Parkinson's disease and dementia with Lewy bodies, establishing a disease mechanism relevant to assessing variants.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here, we have investigated the functional effects of this novel mutation on phospholipid binding and filament assembly of a-synuclein.",
          "judgment": "Yes",
          "reasoning": "The assays used (phospholipid binding and filament assembly) are commonly employed to investigate the pathological mechanisms associated with a-synuclein aggregation and protein-lipid interactions, which are central to the disease.",
          "next_step_or_outcome": "Proceed to Step 1a of Step 3"
        },
        {
          "step_name": "Step 1a: Basic Controls and Replicates - Controls",
          "extracted_paper_info": "When compared to the wild-type protein, the E46K mutation caused a signiﬁcantly increased ability of a-synuclein to bind to negatively charged liposomes.",
          "judgment": "Yes",
          "reasoning": "The comparison to wild-type protein serves as a negative control."
        },
        {
          "step_name": "Step 1b: Basic Controls and Replicates - Replicates",
          "extracted_paper_info": "N/A - The paper does not explicitly mention replicates.",
          "judgment": "No",
          "reasoning": "The absence of information about replicates makes assessing the rigor of the experiments difficult, so proceed to Step 1b of Step 3."
        },
        {
          "step_name": "Step 1b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a).",
          "extracted_paper_info": "N/A",
          "judgment": "No",
          "reasoning": "Since there are insufficient replicates, the assays are not considered accepted or validated. Proceed to Max PS3_supporting / Max BS3_supporting.",
          "next_step_or_outcome": "Proceed to Step 1c of Step 3"
        },
        {
          "step_name": "Step 1c: Variant Controls",
          "extracted_paper_info": "N/A - The paper does not mention use of pathogenic or benign variant controls.",
          "judgment": "No",
          "reasoning": "The paper does not mention use of pathogenic or benign variant controls.  Proceed to Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "functional_evidence_strength": "Max PS3_supporting"
    }
  ]
}